DNA Script logo

DNA Script SAS

Biotechnology

DNA Script Stock

DNA Script is a biotechnology company revolutionizing DNA synthesis with its proprietary Enzymatic DNA Synthesis (EDS) technology. Their flagship product, the SYNTAX System, enables rapid, on-demand DNA oligo production in-house, offering researchers greater control, speed, and flexibility for various applications in genomics and personalized medicine.

Founded: 2014

DNA Script Website

For more DNA Script stock information, or to buy or sell private shares, sign up for a MicroVentures account.

DNA Script Company Overview

Founded to address the inherent limitations of traditional chemical DNA synthesis, DNA Script is a pioneering biotechnology company specializing in Enzymatic DNA Synthesis (EDS). Established by a team of experts in molecular biology, chemistry, and engineering, DNA Script is headquartered in Paris, France, with additional operations in the United States. The company's mission is to revolutionize the field of DNA synthesis, providing researchers with faster, more efficient, and environmentally sustainable tools for molecular biology. DNA Script's flagship product, the SYNTAX System, represents a breakthrough in DNA synthesis technology. Unlike conventional methods that rely on hazardous chemicals, the SYNTAX System uses enzymes to synthesize DNA oligonucleotides. This enzymatic approach not only reduces the environmental impact but also enhances the speed and accuracy of DNA synthesis. The SYNTAX System is designed for in-house use, allowing researchers to produce custom DNA oligos on-demand. This capability is crucial for applications in genomics, personalized medicine, synthetic biology, and other fields where rapid prototyping and iteration of DNA sequences are essential. The SYNTAX System offers several key advantages, including improved control over the synthesis process, reduced turnaround times, and elimination of the need to outsource DNA synthesis. This level of control and flexibility enables researchers to quickly adapt to changing experimental needs and accelerate their research timelines. Additionally, DNA Script's technology enhances data security by keeping sensitive genetic information within the laboratory, thus mitigating the risks associated with external DNA synthesis services. DNA Script's innovative approach has garnered significant attention and investment, positioning the company at the forefront of the biotech industry. The company continues to advance its technology, aiming to expand the capabilities of enzymatic DNA synthesis and further democratize access to high-quality DNA synthesis tools. By empowering researchers with state-of-the-art technology, DNA Script is driving innovation and enabling new discoveries in the life sciences.

Management Team

Sylvian Gariel Co-Founder and Chief Operating Officer
Thomas Ybert Co-Founder and Chief Executive Officer
Xavier Godron Co-Founder and Chief Technology Officer
Philppe Lyko Chief Financial Officer

Funding Information